474 — Aceso Life Science Income Statement
0.000.00%
Last trade - 00:00- HK$1.24bn
- HK$2.10bn
- HK$58.00m
Annual income statement for Aceso Life Science, fiscal year end - March 31st, HKD millions except per share, conversion factor applied.
2022 March 31st | 2023 March 31st | 2024 March 31st | R2025 March 31st | 2026 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | HKAS | HKAS | HKAS | HKAS | HKAS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 315 | 312 | 228 | 50 | 58 |
| Cost of Revenue | |||||
| Gross Profit | 162 | 141 | 117 | — | — |
| Selling / General / Administrative Expenses | |||||
| Operating Interest Expense / Income | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 637 | 187 | 585 | 593 | 361 |
| Operating Profit | -322 | 125 | -357 | -543 | -303 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -555 | -213 | -823 | -659 | -421 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -596 | -208 | -809 | -651 | -429 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -370 | -264 | -462 | -757 | 338 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -370 | -264 | -462 | -757 | 338 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.053 | -0.046 | -0.057 | -0.083 | -0.028 |